• PAVmed posted a GAAP net loss attributable to common stockholders of USD 7 million, or USD 4.42 per diluted share, while operating expenses increased to USD 8.1 million.
• Revenue rose to USD 22,000, while cash and cash equivalents climbed to USD 6.5 million as of March 31, 2026.
• Veris Health advanced development of its implantable physiological monitor toward a planned FDA 510(k) submission, with presubmission and testing activities expected to begin soon.
• Lucid Diagnostics recognized USD 1.3 million of EsoGuard revenue on 3,177 tests, while its underwritten common stock offering netted about USD 17 million in proceeds.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PAVmed Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY60645) on May 15, 2026, and is solely responsible for the information contained therein.